Evidence map›Paper›PMID 38985674›Full record

ArticleCell reports2024

SART3 reads methylarginine-marked glycine- and arginine-rich motifs.

Yalong Wang, Jujun Zhou, Wei He, Rongjie Fu, Leilei Shi, Ngoc Khoi Dang, Bin Liu, Han Xu, Xiaodong Cheng, Mark T Bedford

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yalong WangDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jujun ZhouDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wei HeDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rongjie FuDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Leilei ShiDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ngoc Khoi DangDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bin LiuDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Han XuDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaodong ChengDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark T BedfordDepartment of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mtbedford@mdanderson.org.

Funding

Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and MechanismsR35GM134744 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Xiaodong Cheng · 2020 to 2026
$4.5M
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancerR01CA272843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD, Pawel K. Mazur · 2023 to 2026
$2.6M
Computational approaches for protein functional analysis using CRISPR screensR35GM137927 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI XU, HAN · 2020 to 2024
$2.0M
A Functional Analysis of Arginine MethylationR35GM153387 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD · 2024 to 2026
$1.2M
NCI NIH HHS R01 CA272843NIGMS NIH HHS R35 GM134744NIGMS NIH HHS R35 GM137927NIGMS NIH HHS R35 GM153387
6 · The paper itself

Abstract

Glycine- and arginine-rich (GAR) motifs, commonly found in RNA-binding and -processing proteins, can be symmetrically (SDMA) or asymmetrically (ADMA) dimethylated at the arginine residue by protein arginine methyltransferases. Arginine-methylated protein motifs are usually read by Tudor domain-containing proteins. Here, using a GFP-Trap, we identify a non-Tudor domain protein, squamous cell carcinoma antigen recognized by T cells 3 (SART3), as a reader for SDMA-marked GAR motifs. Structural analysis and mutagenesis of SART3 show that aromatic residues lining a groove between two adjacent aromatic-rich half-a-tetratricopeptide (HAT) repeat domains are essential for SART3 to recognize and bind to SDMA-marked GAR motif peptides, as well as for the interaction between SART3 and the GAR-motif-containing proteins fibrillarin and coilin. Further, we show that the loss of this reader ability affects RNA splicing. Overall, our findings broaden the range of potential SDMA readers to include HAT domains.

Indexed as

Amino Acid MotifsArginineGlycineChromosomal Proteins, Non-HistoneHEK293 CellsHumansMethylationProtein-Arginine N-MethyltransferasesProtein BindingRNA-Binding ProteinsRNA SplicingArginineChromosomal Proteins, Non-HistonefibrillarinGlycineProtein-Arginine N-MethyltransferasesRNA-Binding Proteinsarginine methylationCP: Molecular biologyRNA splicingSART3TPR domain

Identifiers

PMID38985674
PMCPMC11370311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.